Published in Eur J Heart Fail on September 18, 2008
Plasma neutrophil gelatinase-associated lipocalin is independently associated with cardiovascular disease and mortality in community-dwelling older adults: The Rancho Bernardo Study. J Am Coll Cardiol (2012) 1.84
Serum neutrophil gelatinase-associated lipocalin (NGAL) in predicting worsening renal function in acute decompensated heart failure. J Card Fail (2009) 1.75
Tubular damage in chronic systolic heart failure is associated with reduced survival independent of glomerular filtration rate. Heart (2010) 1.50
Prognostic utility of plasma neutrophil gelatinase-associated lipocalin in patients with acute heart failure: the NGAL EvaLuation Along with B-type NaTriuretic Peptide in acutely decompensated heart failure (GALLANT) trial. Eur J Heart Fail (2011) 1.48
Prevalence of chronic kidney disease and progression of disease over time among patients enrolled in the Houston West Nile virus cohort. PLoS One (2012) 1.37
Lack of significant renal tubular injury despite acute kidney injury in acute decompensated heart failure. Eur J Heart Fail (2012) 1.10
Biomarkers: optimizing treatment guidance in heart failure. Clin Res Cardiol (2011) 1.05
Acute kidney injury biomarkers for patients in a coronary care unit: a prospective cohort study. PLoS One (2012) 1.02
Neutrophil gelatinase-associated lipocalin as a biomarker of cardiovascular disease: a systematic review. Clin Chem Lab Med (2012) 0.98
Renal dysfunction is a stronger determinant of systemic neutrophil gelatinase-associated lipocalin levels than myocardial dysfunction in systolic heart failure. J Card Fail (2011) 0.97
Lipocalin-2 induces cardiomyocyte apoptosis by increasing intracellular iron accumulation. J Biol Chem (2011) 0.95
Neutrophil gelatinase-associated lipocalin: ready for routine clinical use? An international perspective. Blood Purif (2014) 0.94
Novel urinary biomarkers in detecting acute kidney injury, persistent renal impairment, and all-cause mortality following decongestive therapy in acute decompensated heart failure. J Card Fail (2013) 0.89
Plasma neutrophil gelatinase-associated lipocalin for the prediction of acute kidney injury in acute heart failure. Crit Care (2012) 0.86
Heart-kidney biomarkers in patients undergoing cardiac stress testing. Int J Nephrol (2010) 0.86
Sepsis and AKI in ICU Patients: The Role of Plasma Biomarkers. Crit Care Res Pract (2012) 0.85
Biomarkers for chronic heart failure : diagnostic, prognostic, and therapeutic challenges. Herz (2009) 0.85
Elevated urinary neutrophil gelatinase-associated lipocalcin after acute heart failure treatment is associated with worsening renal function and adverse events. Eur J Heart Fail (2012) 0.84
Neutrophil Gelatinase-Associated Lipocalin (NGAL) predicts renal injury in acute decompensated cardiac failure: a prospective observational study. BMC Cardiovasc Disord (2012) 0.84
Animal models of cardiorenal syndrome: a review. Heart Fail Rev (2012) 0.84
Laboratory parameters of cardiac and kidney dysfunction in cardio-renal syndromes. Heart Fail Rev (2011) 0.83
Improved functional recovery to I/R injury in hearts from lipocalin-2 deficiency mice: restoration of mitochondrial function and phospholipids remodeling. Am J Transl Res (2012) 0.82
Current and novel renal biomarkers in heart failure. Heart Fail Rev (2012) 0.81
Cardiac biomarkers: new tools for heart failure management. Cardiovasc Diagn Ther (2012) 0.81
Renal dysfunction in acute heart failure: epidemiology, mechanisms and assessment. Heart Fail Rev (2012) 0.81
Urinary neutrophil gelatinase-associated lipocalin as a predictor of cardiovascular events in patients with chronic kidney disease. Heart Vessels (2013) 0.80
The prevalence of chronic kidney disease in a primary care setting: a Swiss cross-sectional study. PLoS One (2013) 0.80
Novel renal biomarkers to assess cardiorenal syndrome. Curr Heart Fail Rep (2014) 0.80
Evaluation of chronic kidney disease in chronic heart failure: From biomarkers to arterial renal resistances. World J Clin Cases (2015) 0.80
Additive clinical value of serum brain-derived neurotrophic factor for prediction of chronic heart failure outcome. Heart Vessels (2015) 0.79
Cardiorenal biomarkers in acute heart failure. J Geriatr Cardiol (2012) 0.78
Incorporating common biomarkers into the clinical management of heart failure. Curr Heart Fail Rep (2013) 0.78
Emerging biomarkers in heart failure and cardiac cachexia. Int J Mol Sci (2014) 0.78
Novel Biomarkers for Cardio-renal Syndrome. Electrolyte Blood Press (2012) 0.76
The role of urine neutrophil gelatinase--associated lipocalin (NGAL) in acute heart failure in patients with ST--elevation myocardial infarction. BMC Cardiovasc Disord (2015) 0.75
Acute kidney injury prediction in cardiac surgery patients by a urinary peptide pattern: a case-control validation study. Crit Care (2016) 0.75
Renocardiovascular Biomarkers: from the Perspective of Managing Chronic Kidney Disease and Cardiovascular Disease. Front Cardiovasc Med (2017) 0.75
Serum lipocalin-2 levels are positively associated with not only total body fat but also visceral fat area in Chinese men. Medicine (Baltimore) (2016) 0.75
Long-term changes in renal function and perfusion in heart failure patients with reduced ejection fraction. Clin Res Cardiol (2015) 0.75
Increased Susceptibility to Structural Acute Kidney Injury in a Mouse Model of Presymptomatic Cardiomyopathy. Am J Physiol Renal Physiol (2017) 0.75
Prognostic Significance of Interleukin-34 (IL-34) in Patients With Chronic Heart Failure With or Without Renal Insufficiency. J Am Heart Assoc (2017) 0.75
Prognostic Value of Urinary Neutrophil Gelatinase-Associated Lipocalin on the First Day of Admission for Adverse Events in Patients With Acute Decompensated Heart Failure. J Am Heart Assoc (2017) 0.75
Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med (2010) 14.43
Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature (2011) 13.25
Genome-wide association study identifies eight loci associated with blood pressure. Nat Genet (2009) 12.44
Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med (2010) 8.17
Rosuvastatin in older patients with systolic heart failure. N Engl J Med (2007) 7.55
Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation (2002) 7.25
Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet (2012) 6.42
Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int (2004) 6.32
Prognostic association of depression following myocardial infarction with mortality and cardiovascular events: a meta-analysis. Psychosom Med (2004) 6.00
The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet (2012) 4.87
Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med (2013) 4.67
Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol (2007) 4.19
Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. Eur J Heart Fail (2010) 3.90
Identification of seven loci affecting mean telomere length and their association with disease. Nat Genet (2013) 3.87
Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation (2006) 3.85
Genetic loci influencing kidney function and chronic kidney disease. Nat Genet (2010) 3.75
Culprit vessel only versus multivessel and staged percutaneous coronary intervention for multivessel disease in patients presenting with ST-segment elevation myocardial infarction: a pairwise and network meta-analysis. J Am Coll Cardiol (2011) 3.66
Immediate postoperative renal function deterioration in cardiac surgical patients predicts in-hospital mortality and long-term survival. J Am Soc Nephrol (2004) 3.63
Common variants in 22 loci are associated with QRS duration and cardiac ventricular conduction. Nat Genet (2010) 3.55
B-type natriuretic peptide and prognosis in heart failure patients with preserved and reduced ejection fraction. J Am Coll Cardiol (2013) 3.54
Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J Am Coll Cardiol (2005) 3.53
Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. Clin Res Cardiol (2010) 3.50
Digoxin reduces 30-day all-cause hospital admission in older patients with chronic systolic heart failure. Am J Med (2013) 3.46
Plasma concentration of amino-terminal pro-brain natriuretic peptide in chronic heart failure: prediction of cardiovascular events and interaction with the effects of rosuvastatin: a report from CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure). J Am Coll Cardiol (2009) 3.32
Increased central venous pressure is associated with impaired renal function and mortality in a broad spectrum of patients with cardiovascular disease. J Am Coll Cardiol (2009) 3.31
Genome-wide meta-analysis identifies 11 new loci for anthropometric traits and provides insights into genetic architecture. Nat Genet (2013) 3.25
New gene functions in megakaryopoiesis and platelet formation. Nature (2011) 3.14
Sodium intake, ACE inhibition, and progression to ESRD. J Am Soc Nephrol (2011) 3.13
Genome-wide association analyses identify 18 new loci associated with serum urate concentrations. Nat Genet (2012) 3.04
Common variants near TERC are associated with mean telomere length. Nat Genet (2010) 2.98
Sex-stratified genome-wide association studies including 270,000 individuals show sexual dimorphism in genetic loci for anthropometric traits. PLoS Genet (2013) 2.83
Compliance in heart failure patients: the importance of knowledge and beliefs. Eur Heart J (2005) 2.81
Seventy-five genetic loci influencing the human red blood cell. Nature (2012) 2.77
FTO genotype is associated with phenotypic variability of body mass index. Nature (2012) 2.77
Worsening renal function and prognosis in heart failure: systematic review and meta-analysis. J Card Fail (2007) 2.77
Adherence to guidelines is a predictor of outcome in chronic heart failure: the MAHLER survey. Eur Heart J (2005) 2.74
CUBN is a gene locus for albuminuria. J Am Soc Nephrol (2011) 2.70
Assessing and grading congestion in acute heart failure: a scientific statement from the acute heart failure committee of the heart failure association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine. Eur J Heart Fail (2010) 2.64
Anemia and mortality in heart failure patients a systematic review and meta-analysis. J Am Coll Cardiol (2008) 2.59
A single dose of erythropoietin in ST-elevation myocardial infarction. Eur Heart J (2010) 2.52
Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial. J Clin Oncol (2010) 2.51
Predictive performance of renal function equations in renal transplant recipients: an analysis of patient factors in bias. Am J Transplant (2005) 2.46
Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. Eur Heart J (2013) 2.45
Peripartum cardiomyopathy as a part of familial dilated cardiomyopathy. Circulation (2010) 2.41
Symptom dimensions of depression following myocardial infarction and their relationship with somatic health status and cardiovascular prognosis. Am J Psychiatry (2006) 2.41
Albuminuria, proteinuria, and novel urine biomarkers as predictors of long-term allograft outcomes in kidney transplant recipients. Am J Kidney Dis (2011) 2.38
Telomere length of circulating leukocytes is decreased in patients with chronic heart failure. J Am Coll Cardiol (2007) 2.36
Drawbacks and prognostic value of formulas estimating renal function in patients with chronic heart failure and systolic dysfunction. Circulation (2006) 2.35
Microalbuminuria and risk of venous thromboembolism. JAMA (2009) 2.35
Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a community-based cohort: 11-year follow-up of PREVEND. Eur Heart J (2013) 2.32
Comparison between the prognostic value of left ventricular function and myocardial perfusion reserve in patients with ischemic heart disease. J Nucl Med (2009) 2.31
Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation (2004) 2.30
Relationship between left ventricular dysfunction and depression following myocardial infarction: data from the MIND-IT. Eur Heart J (2005) 2.28
Adequacy of endogenous erythropoietin levels and mortality in anaemic heart failure patients. Eur Heart J (2008) 2.26
Genome-wide association study of blood pressure extremes identifies variant near UMOD associated with hypertension. PLoS Genet (2010) 2.24
Effect of moderate or intensive disease management program on outcome in patients with heart failure: Coordinating Study Evaluating Outcomes of Advising and Counseling in Heart Failure (COACH). Arch Intern Med (2008) 2.23
Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med (2010) 2.21
Endogenous erythropoietin and outcome in heart failure. Circulation (2010) 2.19
Effect of lenient versus strict rate control on cardiac remodeling in patients with atrial fibrillation data of the RACE II (RAte Control Efficacy in permanent atrial fibrillation II) study. J Am Coll Cardiol (2011) 2.19